# IAP12 Rec'd PCT/PTO 25 AUG 2006

## PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q96728

Johnathan Michael WHITE, et al.

Appln. No.: Based on PCT/AU05/000266

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: August 25, 2006

Examiner: Unknown

For:

**CELL TARGETING CONJUGATES** 

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

#### MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/590784

IAP12 Rec'd PCT/PTO 25 AUG 2006

INFORMATION DISCLOSURE STATEMENT U.S. Appln. No.: Based on PCT/AU05/000266

Attorney Docket No.: Q96728

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 32,197

Mark Boland

SUGHRUE MION, PLLC Mark Boland

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: August 25, 2006

10/590784

MODIFIED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO			IAPT2 Recent PCT #REQ 2 5 AUG 2006			
Substitute for Portificial	9 A & B/F10			Application Number Based on PCT/AU05/0		
INFOR	RMATION	DISCLOS	TIRE	Confirmation Number	Unknown	
	FORMATION DISCLOSURE FATEMENT BY APPLICANT			Filing Date	August 25, 2006	
STATEMENT BY APPLICAN			ANI	First Named Inventor	Johnathan Michael WHITE	
(use as many sheets as necessary)				Art Unit	Unknown	
•				Examiner Name	Unknown	
Sheet	1	of	1	Attorney Docket Number	Q96728	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number		Publication Date		
		Number	Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
		US 5,579,514	A	06-02-1998	M. Jules Mattes	
		US				
		US				
		US				
		US				
		US				
		US				
	-	US				
		US		-		

FOREIGN PATENT DOCUMENTS								
Examiner Cito Initials* No.	Cite	Foreign Patent Document			Publication Date	Name of Patentee or		
	No.1	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>	
		wo	97/004776	Al	02-13-1997	PETER MACCALLUM CANCER INSTITUTE		
				-				
			T					

Examiner Cite Initials* No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		STN File CA, Abstract 134:291615, T.G. MINEHAN, et al., "Molecular recognition of DNA by Hoechst benzimidazoles: exploring beyond the pyrrole-imidazole-hydroxypyrrole polyamide-pairing code", Helvetica Chimica Acta, 2000, pp. 2197-2213, Vol. 83, No. 9		
		STN File CA, Abstract 126:235131, S. FRAU, et al., :Nuclease activity and binding characteristics of a catatonic 'manganese porphyrin-bis (benzimidazole) dye (Hoechst 33258)' conjugate", Bioconjugate Chemistry, 1997, pp. 222-231, Vol. 8, No. 2		
		STN File CA, Abstract 124:444084, S, FRAU, et al., "Synthesis and characterization of a cationic 'manganese porphyrin-bisbenzimidazole dye (Hoest 33258)' conjugate as a potential sequence-selective DNA cleaver", New Journal of Chemistry, 1995, pp. 873-876, Vol. 19, No. 8-9		
		STN File CA, Abstract 115:250504, S.D. IVANOV, et al., "Spectral properties of bisbenzimidasoles interacting with nucleic acids", Bioorganicheskaya Khimiya, 1991, pp. 1041-1047, Vol. 17, No. 8  International Search Report dated April 15, 2005		

	l .			
			<b>,</b>	
Examiner Signature		Date Considered		
Examinet Officiatore		Date Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.